Clinical Comprehensive Evaluation of Yuxintong Capsules in the Treatment of Coronary Heart Disease Angina Pectoris
QIAO Lijie
PI Zheyu
ZHAO Ruixia
GUO Hongxin
LI Rui
LI Yizhen
XING Yunfei
WANG Yongxia
LI Bin
Abstract：Objective:A comprehensive clinical evaluation was conducted on the treatment of coronary heart disease with Yuxintong Capsules to clarify its application value,ensure medication safety,guide rational drug use,and provide a scientific basis for the inclusion of these drugs in the national essential medicine list.Methods:In accordance with the"Guidelines for Clinical Comprehensive Evaluation of Drugs(Trial Version 2021)",based on the relevant materials,literature,and questionnaires provided by the enterprise,a comprehensive clinical evaluation was conducted on the performance of Yuxintong Capsules and its three comparison drugs in the treatment of coronary heart disease and angina pectoris.The evaluation was carried out from six core aspects:safety,effectiveness,economy,innovation,suitability,and accessibility.Results:In terms of safety,no toxic reactions were observed,and no serious adverse reactions were noted.In terms of effectiveness,compared with conventional Western medicine alone,Yuxintong Capsules could significantly improve the clinical efficacy and electrocardiogram efficacy of patients with coronary heart disease and angina pectoris,reduce the frequency and duration of angina pectoris attacks,and alleviate the degree of physical activity limitation in the Seattle Angina Questionnaire score.Terms of economy,Yuxintong Capsules had more advantageous performance and effect.In terms of innovation,Yuxintong Capsules showed significant advantages over traditional pharmaceuticals.Yuxintong Capsules could enhance the exercise tolerance of patients with stable coronary heart disease.In terms of suitability,this drug showed excellent suitability in both its pharmaceutical technical characteristics and clinical application.In terms of accessibility,the supply of medicines was abundant.The raw materials did not involve endangered animal medicinal materials.and the accessibility was good.The expert group's recommendation was of category A(13/13),and it could be directly converted into a decision-making basis.Conclusion:The Yuchxintong Capsules have shown excellent performance in the treatment of coronary heart disease angina pectoris,possess significant clinical value.
Keywords：coronary heart disease angina pectorisYuxintong Capsulesclinical comprehensive evaluation
Publication Date：2025-10-10
Online Publishing Date：2025-10-24(First online date of this platform, not the publication date of the document)
Pages：7( 2889-2895 )